Shares of HCW Biologics plunged nearly 28% over the past week, falling from $3.17 to $2.28, after the clinical-stage biotech disclosed second-quarter results that cast serious doubt on whether the company can stay afloat without fresh cash. HCW Biologics Warns It May Not Survive the Year — Is There Enough Science to Justify the Gamble?
Shares of HCW Biologics cratered nearly 28% in five trading sessions, sinking to $2.28, after the clinical-stage biotech disclosed a second-quarter loss that more than doubled and repeated a stark warning: it may not be able to keep the lights on without new money.
• Losses Tripled While Revenue Stayed Negligible
The Q2 net loss ballooned to $5.2 million, up from $1.9 million a year ago.
Revenue from licensing activities rose to just $135,568 from $6,550 in the prior-year quarter — a big percentage jump on a tiny base that does nothing to offset the cash burn. The company reported ($11.58) earnings per share, missing analysts' consensus estimate of ($1.98) by $9.60. For shareholders, the math is brutal: expenses are climbing while meaningful revenue remains a distant prospect.
• The Company Itself Says It Might Not Make It
As of June 30, 2026, HCW Biologics said there is "substantial doubt" about its ability to continue as a going concern — meaning stay in business — for at least 12 months without additional funding. This isn't new; at the end of Q1, management disclosed cumulative net losses of $102.3 million and cash of just $1.23 million.
Independent analysis confirms HCWB has less than a year of cash runway at its current burn rate. Any capital raise at a $4.29 million market cap would massively dilute existing holders.
• Clinical Hope Is Real but Far Off
In June the company shared preliminary human data from the first two dose cohorts of a Phase 1 trial testing its lead drug candidate for alopecia areata, an autoimmune hair-loss condition.
Management says its strategy hinges on business development deals and selling commercial-ready ingredients used in making cancer and infectious-disease treatments. But early-stage trial data won't generate product revenue for years, and licensing deals have been sporadic — Q1's $6.5 million revenue windfall came entirely from a single one-time license transaction.
• Nasdaq Delisting Risk Adds Another Layer of Danger
In late June, the company received notice it had regained compliance with Nasdaq's $1.00 minimum bid price rule , but the stock's steep slide puts that status back in jeopardy. With a market cap of just $4.29 million and a beta of 2.32 — meaning the stock swings more than twice as wildly as the broader market — HCWB is now a survival bet. Investors are wagering that new funding or a partnership materializes before the cash runs dry. The odds, based on the numbers, are not encouraging.